(RTTNews) - Sanofi said the FDA has granted fast track designation to SAR402663, an investigational one-time intravitreal gene therapy for the treatment of neovascular age-related macular degeneration. Sanofi is currently evaluating SAR402663 in a phase 1/2 for the treatment of patients with neovascular AMD. SAR402663 delivers genetic material encoding soluble FLT01 designed to inhibit vascular endothelial growth factor.
The fast-track designation process aims to facilitate the development and expedite the review of medicines to treat serious conditions and fill unmet medical need.
For More Such Health News, visit rttnews.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
